Crispr Therapeutics (CRSP) Trading 6% Higher
Shares of Crispr Therapeutics AG (NASDAQ:CRSP) traded up 6% during mid-day trading on Monday . The stock traded as high as $58.25 and last traded at $56.67. 1,835,412 shares changed hands during trading, an increase of 153% from the average session volume of 724,122 shares. The stock had previously closed at $53.46.
Several analysts have recently issued reports on the company. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 13th. Zacks Investment Research raised Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Friday, May 11th. Citigroup reduced their target price on Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating on the stock in a report on Friday, August 24th. TheStreet lowered Crispr Therapeutics from a “c” rating to a “d+” rating in a report on Friday, May 11th. Finally, Chardan Capital increased their target price on Crispr Therapeutics from $25.00 to $72.50 and gave the stock a “buy” rating in a report on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $65.78.
The firm has a market capitalization of $2.70 billion, a PE ratio of -32.49 and a beta of 3.39.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now directly owns 5,816 shares of the company’s stock, valued at $360,592. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 5,816 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $62.00, for a total value of $360,592.00. Following the completion of the sale, the director now directly owns 5,816 shares in the company, valued at $360,592. The disclosure for this sale can be found here. Company insiders own 37.70% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC boosted its stake in Crispr Therapeutics by 8.2% in the first quarter. NEA Management Company LLC now owns 3,484,464 shares of the company’s stock valued at $159,275,000 after buying an additional 263,736 shares in the last quarter. Federated Investors Inc. PA acquired a new stake in Crispr Therapeutics in the second quarter valued at about $37,101,000. BlackRock Inc. boosted its stake in Crispr Therapeutics by 3.7% in the second quarter. BlackRock Inc. now owns 593,527 shares of the company’s stock valued at $34,876,000 after buying an additional 21,309 shares in the last quarter. Orbimed Advisors LLC boosted its stake in Crispr Therapeutics by 375.3% in the second quarter. Orbimed Advisors LLC now owns 496,200 shares of the company’s stock valued at $29,157,000 after buying an additional 391,799 shares in the last quarter. Finally, ARK Investment Management LLC boosted its stake in Crispr Therapeutics by 544.0% in the second quarter. ARK Investment Management LLC now owns 467,140 shares of the company’s stock valued at $27,449,000 after buying an additional 394,606 shares in the last quarter. 38.78% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.